GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
== Shelf-life and safety == The purpose of IMF foods is to achieve a water activity that the food can be stored safely without refrigeration. However, the food is not sterile. Staphylococcus aureus is a microorganism of concern as it can grow and produce specific enterotoxins in water activities of 0.83-0.86 under aerobic conditions. Because of this, proper handling, storage, hygiene and good manufacturing practices are necessary to prevent Staphylococcus aureus. Molds of Aspergillis and Penicillium species can grow and produce harmful mycotoxins at water activity 0.77-0.85. Salmonella and Bacillus cereus are the primary pathogens of concern with low-moisture foods and IMFs. Most illnesses associated with low-moisture foods or IMFs have been caused by Salmonella spp. To reduce the risk of bacterial growth, products are treated with a combination of low pH, addition of sugar, salt and preservatives, and a thermal process that can eliminate pathogens and extend shelf-life. In the case of yeasts and molds, chemical preservatives such as sorbates and propionates are used to inhibit their growth.
In beta cells, insulin release is stimulated primarily by glucose present in the blood. As circulating glucose levels rise, such as after ingesting a meal, insulin is secreted in a dose-dependent fashion. This system of release is commonly referred to as glucose-stimulated insulin secretion (GSIS). There are four key events to the triggering pathway of GSIS: GLUT dependent glucose uptake, glucose metabolism, KATP channel closure, and the opening of voltage gated calcium channels causing insulin granule fusion and exocytosis. Voltage-gated calcium channels and ATP-sensitive potassium ion channels (KATP channels) are embedded in the plasma membrane of beta cells. Under non-glucose stimulated conditions, the KATP channels are open and the voltage gated calcium channels are closed. Via the KATP channels, potassium ions move out of the cell, down their concentration gradient, making the inside of the cell more negative with respect to the outside (as potassium ions carry a positive charge). At rest, this creates a potential difference across the cell surface membrane of -70mV. When the glucose concentration outside the cell is high, glucose molecules move into the cell by facilitated diffusion, down its concentration gradient through glucose transporters (GLUT). Rodent beta cells primarily express the GLUT2 isoform, whereas human beta cells, although also expressing GLUT2, mainly make use of GLUT1 and GLUT3 isoforms. Since beta cells use glucokinase to catalyze the first step of glycolysis, metabolism only occurs around physiological blood glucose levels and above.
Open water fish are usually streamlined like torpedoes to minimize turbulence as they move through the water. Reef fish live in a complex, relatively confined underwater landscape and for them, manoeuvrability is more important than speed, and many of them have developed bodies which optimize their ability to dart and change direction. Many have laterally compressed bodies (flattened from side to side) allowing them to fit into fissures and swim through narrow gaps; some use their pectoral fins for locomotion and others undulate their dorsal and anal fins. Some fish have grown dermal (skin) appendages for camouflage; the prickly leather-jacket is almost invisible among the seaweed it resembles and the tasselled scorpionfish invisibly lurks on the seabed ready to ambush prey. Some like the foureye butterflyfish have eyespots to startle or deceive, while others such as lionfish have aposematic coloration to warn that they are toxic or have venomous spines. Flatfish are demersal fish (bottom-feeding fish) that show a greater degree of asymmetry than any other vertebrates. The larvae are at first bilaterally symmetrical but they undergo metamorphosis during the course of their development, with one eye migrating to the other side of the head, and they simultaneously start swimming on their side. This has the advantage that, when they lie on the seabed, both eyes are on top, giving them a broad field of view. The upper side is usually speckled and mottled for camouflage, while the underside is pale. Some teleosts are parasites.
Sources: en.wikipedia.org
concentration The quantity or abundance of a constituent of a mixture per unit quantity of that mixture; e.g. the amount, in moles, of a dissolved solute per unit volume of a solution, a measure known as molar concentration or molarity. Several different definitions of concentration are widely used in chemistry, including molar concentration, mass concentration, and volume concentration.
Navy Warrant Officer Class 1 D Lennon Chief Petty Officer M Rodway Army Warrant Officer Class 1 Matthew James Anderson, Royal Corps of Signals Warrant Officer Class 1 Rupert St John Hardington Banfield, , Army Air Corps Warrant Officer Class 1 Peter Bernthal, Corps of Royal Electrical and Mechanical Engineers Staff Sergeant Troy David Binding Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Aarron David Butterworth, Corps of Royal Engineers Warrant Officer Class 1 (now Captain) Adam Daniel Cooksey, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Leslie Trevor Dinsmore, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Darren Lee Duckitt, The Royal Yorkshire Regiment Warrant Officer Class 2 Kulbahadur Ghale, The Royal Gurkha Rifles Warrant Officer Class 1 (now Captain) Marc Kevin Giles, , The Mercian Regiment Warrant Officer Class 1 Philip John Greenway, Royal Regiment of Artillery Warrant Officer Class 1 Adam Charles Ireland, The Parachute Regiment Warrant Officer Class 1 Manojkumar Jugjali, The Royal Gurkha Rifles Warrant Officer Class 1 Carley Lorraine Lambert, Royal Regiment of Artillery Warrant Officer Class 1 James Lee Lightfoot, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Daniel Andrew Long, The Rifles Warrant Officer Class 1 James Derek Mayoh, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Stuart Russell McCreadie, Royal Corps of Signals Warrant Officer Class 1 Peter Steven Meager, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 (now Captain) Ryan Daniel O'Neill, The Royal Regiment of Scotland Warrant Officer Class 1 James Edward Phillips, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Michael John Potts, Royal Army Medical Corps Warrant Officer Class 2 Prakash Rai, Royal Army Medical Corps Warrant Officer Class 2 Kyle Reains, Irish Guards Warrant Officer Class 1 James Wright Reid, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 James Oliver Richardson, Royal Regiment of Artillery Warrant Officer Class 1 Aran Christopher Rushe, Royal Army Medical Corps Warrant Officer Class 1 Grant Spencer Sewell-Jones, Royal Corps of Army Music Warrant Officer Class 1 Paul Sheenan, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Melanie Louise Silvester, Adjutant General's Corps (Staff and Personnel Support Branch) Warrant Officer Class 1 (now Captain) Garry Andrew Smurthwaite, The Parachute Regiment Warrant Officer Class 2 David Robert John Steel, The Royal Scots Dragoon Guards Warrant Officer Class 1 John Ian Sweeney, Army Air Corps Warrant Officer Class 2 (now Captain) Trevor Albert Tuhey, Royal Army Physical Training Corps Warrant Officer Class 1 Russell James Underwood, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 George Ferguson Francis Wong Vesi, Adjutant General's Corps (Staff and Personnel Support Branch) Warrant Officer Class 1 (now Captain) Jonathan George Werrett, The Mercian Regiment Warrant Officer Class 1 Joseph Thomas Williams, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Michael James Williams, Royal Corps of Signals Warrant Officer Class 1 David Wood, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Craig Michael Woodall, Royal Army Veterinary Corps Warrant Officer Class 2 Robert Steven Young, Welsh Guards Air Force Warrant Officer (now Flight Lieutenant) J. Blinkhorn Warrant Officer (now Flight Lieutenant) H. Dimeck Warrant Officer (now Flight Lieutenant) F.E. Hunt Warrant Officer D.P. Burke Warrant Officer W.O.R Clements Warrant Officer N.W. Cook Master Aircrew A.R. Davey, Warrant Officer J.C. Foxall Warrant Officer D.G. Jackson Warrant Officer K.E. Jones Warrant Officer E.L. Kerslake Warrant Officer M.E. Larkin Warrant Officer D.A. Lawrence Warrant Officer R. Laycock Warrant Officer B. Moore Warrant Officer C.L.S Old Master Aircrew S.R. Parsons Warrant Officer K.N. Phillips Warrant Officer S.G. Rowbotham Warrant Officer A. Wilson Warrant Officer P.B. Wilson, Warrant Officer S.M. Wooles Acting Warrant Officer K.S. Edwards Acting Warrant Officer A.S. MacDonald Flight Sergeant M.J. Moore Flight Sergeant J.C. O'Grady Flight Sergeant J.A. Simpkins Flight Sergeant C.A. Smith Flight Sergeant P.S. Ware Flight Sergeant L.A. Williams Chief Technician D.G. Bristow Sergeant E.P. Jones
==== Yeast Two-hybrid Screens ==== Yeast two-hybrid analyses have been adapted for protease-substrate discovery. As protease exosites play roles in protein-protein recognition and interaction, biologists have used exosites as tools to screen for protease interactors and potential substrates. These protease exosite scanning assays use protease exosites as bait to scan a cDNA library for possible interacting partners. Another early adaptation of yeast two-hybrid screening in protease-substrate discovery is Inactive-catalytic-domain capture (ICDC). This approach attempts to avoid the limitation of protease exosite scanning, which fails to account for any substrates that do not require exosites to for recognition before cleavage. The bait for these assays are immobilized catalytically inactive mutant protease domains that cannot cleave and release their substrates once bound. While useful in early degradomic studies, the limitations of adapted yeast two-hybrid screens have forced the field to move on to higher-throughput approaches for protease-substrate discovery. Their high rate of false positives and negatives, inability to recognize complex interactions, lack of biologically compartmentalization, and failure to account for post-translational modifications necessary for protein-protein interactions hamper their usefulness. Thus they have been largely replaced by proteomic methods as technology has improved.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.